These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23567085)

  • 1. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.
    Mallat A; Teixeira-Clerc F; Deveaux V; Manin S; Lotersztajn S
    Br J Pharmacol; 2011 Aug; 163(7):1432-40. PubMed ID: 21457226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
    Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
    Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
    Svízenská I; Dubový P; Sulcová A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice.
    Louvet A; Teixeira-Clerc F; Chobert MN; Deveaux V; Pavoine C; Zimmer A; Pecker F; Mallat A; Lotersztajn S
    Hepatology; 2011 Oct; 54(4):1217-26. PubMed ID: 21735467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling.
    Dobrosi N; Tóth BI; Nagy G; Dózsa A; Géczy T; Nagy L; Zouboulis CC; Paus R; Kovács L; Bíró T
    FASEB J; 2008 Oct; 22(10):3685-95. PubMed ID: 18596221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut feelings about the endocannabinoid system.
    Di Marzo V; Piscitelli F
    Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of cannabinoid receptor ligands: current status.
    Singh J; Budhiraja S
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.
    Palumbo-Zerr K; Horn A; Distler A; Zerr P; Dees C; Beyer C; Selvi E; Cravatt BF; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Dec; 71(12):2051-4. PubMed ID: 22915616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health.
    Watkins BA; Hutchins H; Li Y; Seifert MF
    J Nutr Biochem; 2010 Dec; 21(12):1141-52. PubMed ID: 20934863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.